Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Authors of an article published in Clinical Genitourinary Cancer analyzed aspects of laparoscopic treatment of renal cell cancer during pregnancy. Led by Lucio Dell’Atti of the Department of…
The National Science Foundation is providing financial support to a team of biochemists, led by Kent Kirshenbaum, PhD, of New York University, in the quest to create a…
Juan Pascual, MD, PhD, and research associates, have spent the last decade searching for a reliable way to predict seizures. The research team has identified the nerve cells…
Benjamin Prince, MD, MSCI, FAAAAI, allergist/immunologist at Nationwide Children’s Hospital in Columbus, Ohio, discusses when to consider starting IgG replacement therapy. IgG replacement therapy is pooled antibody from…
Benjamin Prince, MD, MSCI, FAAAAI, allergist/immunologist at Nationwide Children’s Hospital in Columbus, Ohio, discusses primary immunodeficiency diseases. Many patients have a genetic defect that results in part of…
A retrospective study’s multivariate analysis suggests that in the treatment of early invasive melanoma, the use of Mohs micrographic surgery is associated with better outcomes when compared with…
Scientists at Brigham and Women’s Hospital are developing a way to bioprint structures that closely mimic ducts and vessels in the human body. This 3D printing technique can…
Devil facial tumor disease (DFTD) is a cancer that can be spread via open wound from Tasmanian devil to Tasmanian devil. William Brown, Project Officer at Department of…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies.…
